Drugs / FWD1802
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07476963 | Mar → Jul 2026 overdue | — | Forward Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07002177 | Jun 2025 → May 2028 expected | estrogen-receptor positive breast cancer | Forward Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06064812 | Sep 2023 → Mar 2026 overdue | Her2-receptor negative breast cancer | Forward Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FWD1802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476963 ↗ |
| Route | Oral | “Subjects enrolled will be orally administered a single dose of FWD1802 Tablet” NCT06064812 ↗ |